Tiantan bio
Tiantan bio
Tiantan bio diagnostic supplies and other biological products
Tiantan Bio is a vaccine reagent developer, focusing on the research and production of vaccines, blood preparations, diagnostic supplies and other biological products, mainly to provide users with hepatitis B vaccine, polio vaccine, MMR vaccine, influenza vaccine, chickenpox vaccine and other products, its own Changchun Chijian Biological Products Co.
- All
- News
- Analysis
- Research
Briefing Sep 21, 2022 10:38 AM
· Healthcare
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
Briefing Sep 16, 2022 11:10 PM
· Healthcare
NaviSeed Nets Tens of millions of CNY in Angel Round
In-depth
Briefing Sep 13, 2022 05:30 PM
· Healthcare
Nuwacell Nets Hundreds of Mns of CNY in Series A
Briefing Aug 31, 2022 08:30 PM
· Healthcare
Enitiatebio Nets One Hundred Million of CNY in Series A Round
Aug 29, 2022 05:45 PM
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Briefing Jun 28, 2022 09:56 AM
· Healthcare
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Briefing Jun 28, 2022 09:54 AM
· Healthcare
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
Briefing Jun 28, 2022 09:50 AM
· Healthcare
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
Briefing Jun 28, 2022 09:37 AM
· Healthcare
Aibo biology: cooperate with Jiahe biology to jointly develop tumor mRNA drugs
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Insight
Healthcare
Blood Cancer, ‘Bloody Invisible Invader’ in China
Blood cancers including leukemia, lymphoma and myeloma are the top 10 cancer diseases worldwide. However, due to their distinct features from solid cancers, the diagnosis of them is much more challenging and requires extra care. Patients possessing blood cancers often have less awareness and blood cancers can be a so-called the invisible invader. This article gives an introduction to blood cancers then generally dissects what challenges the industry is facing in China.
Sep 22, 2022 11:09 AM
Healthcare
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
Briefing Oct 20, 2021 06:11 PM
Five departments including the central bank: encourage financial institutions to incorporate the application of open source technology into their informatization development plans
See more
Related Companies
EqualOcean Analysis